Page last updated: 2024-08-23

daunorubicin and hydromorphone

daunorubicin has been researched along with hydromorphone in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Strassburg, CP; Tukey, RH1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Apfelbaum, SM; Burbage, M; Kircher, S; Kirsch, K; Lofwall, M; Passik, S; Zacny, J1

Reviews

3 review(s) available for daunorubicin and hydromorphone

ArticleYear
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
    Annual review of pharmacology and toxicology, 2000, Volume: 40

    Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic

2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Understanding and treating opioid addiction in a patient with cancer pain.
    The journal of pain, 2011, Volume: 12, Issue:10

    Topics: Adult; Analgesics, Opioid; Antineoplastic Agents; Brain; Cytarabine; Daunorubicin; Heroin Dependence; Hormones; Humans; Hydromorphone; Leukemia, Myeloid; Male; Pain

2011

Other Studies

1 other study(ies) available for daunorubicin and hydromorphone

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004